Skip to main content
. 2020 Jun 13;33(6):1321–1332. doi: 10.1007/s40620-020-00775-4

Table 2.

Demographic data of recipients

Age [mean(SD); median (range)] Gender
Lymphoma = 48 (21) 48 (15.1); 51 (14–69)

M = 22 (46)

F = 18 (37)

NA = 8 (17)

Renal cell carcinoma = 42 (18) 44.2 (16.8); 47.5 (9–69)

M = 27 (64)

F = 12 (29)

NA = 3 (7)

Melanoma = 40 (17) 47.8 (13.4); 47.5 (19–70)

M = 10 (25)

F = 13 (33)

NA = 17 (42)

NSCLC = 13 (6) 38.5 (10); 39 (18–53)

M = 10 (77)

F = 2 (15)

NA = 1 (8)

Neuroendocrine = 11 (5) 44.2 (11.3); 41 (25–64)

M = 5 (45)

F = 4 (36)

NA = 2 (18)

Choriocarcinoma = 10 (4) 29.9 (9.8); 27 (20–47)

M = 2 (20)

F = 6 (60)

NA = 2 (20)

Glioblastoma = 6 (3) 31.5 (11.8); 27.5 (23–48)

M = 2 (33)

F = 2 (33)

NA = 2 (33)

Breast cancer = 5 (2) 38 (19.7); 37.5 (15–62)

M = 3 (60)

F = 2 (40)

Leukemia = 9 (4) 56.8 (17.4); 58 (21–77)

M = 2 (22)

F = 4 (44)

NA = 3 (33)

Other = 50 (21) 47.2 (15.3); 50 (1.42–71)

M = 26 (52)

F = 17 (34)

NA = 7 (14)

Total = 234 (100) 45.4 (15.5); 47 (1.42–77)

M = 109 (47)

F = 80 (34)

NA = 45 (19)

Apart from age, numbers represent absolute values with percentages in parentheses

F female, M male, NA not available, NSCLC non-small cell lung cancer, SD standard deviation